Liz was appointed as an Independent Non-Executive Director on 1 September 2022, and has also been appointed a member of the Audit & Risk and Remuneration Committees.
Liz brings significant experience in commercial biopharmaceuticals and is a seasoned biotech board member. Her significant experience in commercial biopharmaceuticals, both operationally and at Board level, as well as her deep understanding of the biotechnology sector will be invaluable to GSK as we begin our next chapter as a 100% focused biopharma company.
Prior to her current roles, Liz served as Worldwide Vice President and commercial leader in infectious diseases and vaccines and also for immunology and oncology at Janssen Pharmaceuticals, and as Vice President and General Manager at Wyeth Vaccines. Liz was also previously a Board member of Bavarian Nordic A/S and of Huntsworth Plc.
- Board Member, BioMarin Pharmaceutical, Inc.
- Board Member, Revolution Medicines, Inc.
- Board Member, Insmed, Inc.
- She is also a trustee of The Wistar Institute and a director of Aro Biotherapeutics Company, a private company.